Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation

Monique Van Scherpenzeel1,2 · Esther Willems1,2 · Dirk J. Lefeber1,2

Received: 28 August 2015 / Revised: 3 November 2015 / Accepted: 18 November 2015 / Published online: 7 January 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Abnormal protein glycosylation is observed in many common disorders like cancer, inflammation, Alzheimer’s disease and diabetes. However, the actual use of this information in clinical diagnostics is still very limited. Information is usually derived from analysis of total serum N-glycan profiling methods, whereas the current use of glycoprotein biomarkers in the clinical setting is commonly based on protein levels. It can be envisioned that combining protein levels and their glycan isoforms would increase specificity for early diagnosis and therapy monitoring. To establish diagnostic assays, based on the mass spectrometric analysis of protein-specific glycosylation abnormalities, still many technical improvements have to be made. In addition, clinical validation is equally important as well as an understanding of the genetic and environmental factors that determine the protein-specific glycosylation abnormalities. Important lessons can be learned from the group of monogenic disorders in the glycosylation pathway, the Congenital Disorders of Glycosylation (CDG). Now that more and more genetic defects are being unraveled, we start to learn how genetic factors influence glycomics profiles of individual and total serum proteins. Although only in its initial stages, such studies suggest the importance to establish diagnostic assays for protein-specific glycosylation profiling, and the need to look beyond the single glycoprotein diagnostic test. Here, we review progress in and lessons from genetic disease, and review the increasing opportunities of mass spectrometry to analyze protein glycosylation in the clinical diagnostic setting. Furthermore, we will discuss the possibilities to expand current CDG diagnostics and how this can be used to approach glycoprotein biomarkers for more common diseases.

Keywords Congenital disorders of glycosylation · Glycomics · Protein-specific glycosylation · Transferrin

Abbreviations

2DE 2D-electrophoresis
apoC-III apolipoprotein CIII
CA125 cancer antigen 125
CA15-3 cancer antigen 15–3
CA19-9 carbohydrate antigen 19–9
CA27-29 cancer antigen 27–29
CD24 cluster of differentiation 24 or heat stable antigen
CD24 (HSA)
CD59 MAC-inhibitory protein (MAC-IP)
cdg Congenital Disorders of Glycosylation
CDG-I Congenital Disorders of Glycosylation type I
CDG-II Congenital Disorders of Glycosylation type II
CID collision induced energy
COPD Chronic obstructive pulmonary disease
CRC Colorectal cancer
ELISA Enzyme Linked Immunosorbent Assay
ELLA enzyme-linked lectin assay
ETD electron transfer dissociation
FACS fluorescence activated cell sorting
FDA US Food and Drug Administration
FLISA Lectin-Fluorophore-linked Immunosorbent Assay
FRU fructose
FUC fucose
Background

Protein glycosylation is a non-template driven, dynamic, and post-translational modification on top of protein synthesis. Glycans have important functions in many biological processes such as protein folding, clearance and cell-cell interactions. Considering glycosylation to be the final and top level after DNA and protein synthesis, glycosylation is the most informative level, being a product of the genome and environmental factors together. Therefore, the use of glycomics methods to read this information holds enormous potential for the development of unique biomarkers for human diseases. In several genetic and chronic diseases, like cancer [1–3], inflammation [4], Alzheimer’s disease [5], diabetes [6, 7] and metabolic disorders [8], glycosylation of proteins is changed dramatically. Analysis of glycosylation has the benefit that it provides information about the current status of the patient, which enables early diagnosis of disease onset and therapy monitoring.

Still major technological advances have to be made before glycoprotein biomarkers can be widely used in clinical
diagnostics. In addition, clinical validation of potential biomarkers is equally important as well as the knowledge of how to interpret glycosylation abnormalities in the context of a certain disease. Important lessons can be learned by a comparison with a group of well-defined genetic defects, the Congenital Disorders of Glycosylation (CDG). CDG encompasses a group of inherited diseases with abnormal glycan metabolism. According to current nomenclature [9], they are divided into four different biochemical groups, comprising errors in protein N-linked glycosylation, protein O-linked glycosylation, glycolipid and GPI anchor glycosylation, and a group with defects in multiple glycosylation pathways [10]. Over 100 human genetic disorders have been associated with abnormal glycosylation [8, 11], of which at least 50 types are linked to deficient N-glycosylation of serum transferrin, historically referred to as CDG [12]. Because the defective genes are involved in a variety of functionally diverse metabolic pathways, the clinical presentation of CDG subtypes is highly heterogeneous. Clinical phenotypes range from mild to severe and involve multiple or only single affected organs. Examples of clinical symptoms include intellectual disability, seizures, muscle dystrophy, skeletal dysplasia, dysmorphic features, growth retardation, hematological and endocrine abnormalities, which show the widespread requirement of proper glycosylation for the human system [13, 14]. In line with these diverse clinical symptoms, diagnosis can be very challenging. Currently, only transferrin glycosylation analysis is widely used in clinical diagnostics for CDG.

Advanced mass spectrometry (MS) was introduced in CDG research to analyze released glycans from serum proteins [15–17] to gain more detailed insights in the glycan structural abnormalities. The growing contribution of mass spectrometry in the diagnosis of CDG is outlined in a recent review by Sturiale et al. [18]. Intact glycoprotein analysis of transferrin followed after the rapid development of mass spectrometry techniques and has now been added to routine diagnosis [19] and recently to therapy monitoring of CDG [20]. This method for protein-specific analysis has allowed high-resolution annotation of glycan structures, thereby revealing unique glycosylation profiles for specific genetic defects. This shows the potential to include mass spectrometry in specialized diagnostic laboratories and has already improved the diagnostic process by significantly shortening the time to reach a diagnosis.

It can be predicted that more glycosylation disorders will be reported in the near future since at least 2 % of the human genes encodes for proteins involved in glycan biosynthesis and recognition [8], and 5–10 % for proteins involved in Golgi homeostasis with a potential indirect effect on glycan metabolism. In addition, the wide-spread diagnostic application of next-generation sequencing is increasing the speed of CDG gene discovery [21]. The complexity of different glycosylation pathways, and the existence of tissue- and protein-specific glycosylation, indicates that the current use of transferrin as diagnostic marker is only a mere start to apply methods for glycoprotein analysis in a clinical diagnostic setting. In addition, the coming decade will show a merging of monogenic defects with genetic predisposition in more common diseases with abnormal protein glycosylation. Thus, there is a clear need to develop additional glycoprotein biomarkers to grasp the full scope of glycosylation defects in a diagnostic setting, and to learn how to interpret glycosylation abnormalities in the context of more common diseases.

Here, we will first describe the current state of diagnostics and gene identification for CDG. Secondly, we will discuss the potential use of existing plasma glycoprotein biomarkers, and finish with a look to the future in suitable mass spectrometry approaches for analysis of glycoproteins in clinical diagnostics.

CDG diagnostics and gene identification

Defects in the N-glycosylation pathway are the best studied types of CDG. They are localized to the cytoplasm and the endoplasmic reticulum (ER) in CDG-I or to the cytoplasm and Golgi apparatus in CDG-II [22]. CDG-I defects are characterized by unoccupied glycosylation sites on proteins, thus lacking complete N-glycans, whereas CDG-II defects show immature, truncated glycans. Currently, the first line screening for these CDG subgroups in the majority of metabolic laboratories world-wide is based on the analysis of transferrin N-glycosylation by isoelectric focusing (TIEF), first introduced in 1984 by Jaeken et al. [23], by HPLC [24] or by capillary electrophoresis (CE) [25, 26]. These techniques allow separation of transferrin isoforms on basis of charge state determined by the number of terminal sialic acid residues (see Fig. 1). Normal plasma transferrin contains two complex type N-glycans with in total four terminal sialic acid residues as most dominant species (lanes 1 and 3). CDG patients show a decrease of this tetrasialo transferrin isoform and an increase of lower sialylated species. Abnormal profiles are classified as either CDG-I or CDG-II, depending on an isolated increase of asialo- and disialotransferrin bands (lane 2, CDG-I) or an additional increase of monosialo- and trisialotransferrin bands (lanes 4, 5 and 6, CDG-II), respectively [27]. Diagnostic interpretation of abnormal profiles can be complicated by the presence of transferrin polymorphisms that co-migrate with abnormally glycosylated transferrin isoforms [28, 29] (example in lane 8, Fig. 1). Treatment of serum transferrin (in vitro) with neuraminidase (sialidase), or alternatively analysis of parental plasma samples, is used to confirm or exclude a transferrin polymorphism [30] (lanes 6 to 9). Secondary causes of abnormal transferrin glycosylation are for example alcohol abuse, resulting in CDG-I profiles, the presence of sialidase in the plasma, or severe liver disease, both resulting in CDG-II profiles. In the majority of cases, CDG-I and -II profiles can be clearly discriminated. However, very mild CDG-I profiles can
be interpreted as mild CDG-II (Fig. 1, lane 6) [31], and recently a first genetic defect was reported with a mixed CDG-I/II profile due to a combination of missing and truncated glycans (Fig. 1, lane 7) [20].

Conventionally, the follow up in case of CDG-I profiles consists of enzyme analysis in fibroblasts or leukocytes to diagnose PMM2-CDG, which is the most common type [32], or PMI-CDG. If excluded, the next step is analysis of dolichol- or lipid-linked oligosaccharides (LLO) in fibroblasts [33]. Nowadays, this is being replaced by whole exome sequencing using a filter for CDG-I genes [34], or targeted sequencing of a CDG-I gene panel. Alternatively, direct application of whole exome sequencing without prior CDG screening increasingly results in the identification of CDG defects, which need to be confirmed with Sanger sequencing. A combination of Capillary Electrophoresis [26] or LC [19] with mass spectrometry as a quick and sensitive test could functionally confirm the genetic defect. Also for confirmation of mild CDG-I profiles, mixed CDG-I/II profiles and even for further subtyping of CDG-I defects (such as ALG1-CDG, own data), high-resolution mass spectrometry of intact transferrin can be used.

The standard procedure for CDG-II patterns includes a follow up by isoelectric focusing of plasma apolipoprotein C-III (apoC-III-IEF) to discriminate between isolated N-glycosylation defects and a combined disorder of N- and mucin type O-glycosylation [35]. In addition, two-dimensional electrophoresis with immunoblotting was reported to separate and detect the isoforms of apoC-III, alpha-antitrypsin, alpha-1 acid glycoprotein, haptoglobin and transferrin [36]. Since CDG-II is characterized by truncated glycans, mass spectrometry methods can provide additional insights into the underlying genetic defect. Several methods have been reported for the analysis of transferrin glycopeptides [15, 37] and analysis of whole serum N-glycans [16, 38, 39] by MALDI-TOF mass spectrometry. With respect to O-glycans, mass spectrometry analysis of apoC-III [40] and combined mass spectrometry of released serum N- and O-glycans [41] have been reported. Recently, mass spectrometry analysis of apoC-III O-glycosylation was compared with two-dimensional electrophoresis by Yen-Nicolaÿ et al. and appeared to be a promising technique for analysis of defects in mucin O-glycosylation [42]. Application of high-resolution QTOF mass spectrometry for analysis of intact transferrin allowed to accurately annotate glycan structures on the level of the intact protein [31, 43] and proved highly efficient in subgrouping of CDG-II patients. For example, highly characteristic profiles can be observed for MAN1B1-CDG, PGM1-CDG with a characteristic combined CDG-I/II profile, and SLC35A2-CDG. The method has been validated for use in a clinical metabolic laboratory. The successful identification of gene defects directly from a characteristic glycoprofile of transferrin, has placed this method as second test immediately following CDG screening (diagnostic flowchart shown in [31]).

Currently, mass spectrometry of total serum N-glycans and of transferrin N-glycans has been included in only a few metabolic diagnostic laboratories. However, the high sensitivity and high specificity have already resulted in a significant shortening of the time to reach a genetic diagnosis in CDG, thereby showing the advantage to use mass spectrometry more broadly in CDG diagnostics.

**Therapy monitoring in CDG**

Although many new glycosylation disorders have been identified in the last decade, only little progress has been made in development of new therapies. Different future therapeutic approaches have been proposed for the most common CDG type, PMM2-CDG, in a very comprehensive review by Freeze [44]. These include gene therapy, enzyme enhancement, enzyme replacement, bypassing the metabolic pathway and substrate supplementation. Most of these therapeutic strategies
would be applicable to other CDG types as well, but are still under development. Several challenges have to be overcome, like the lack of appropriate model systems, high costs, small number of patients and the limited bioavailability of the drugs to reach their target, especially in regard to pass the blood–brain-barrier [44]. Only in four CDG subtypes, namely MPI-CDG, PGM1-CDG, SLC35C1-CDG and PIGM-CDG, a mechanism-based treatment has been applied [20, 45–48].

MPI-CDG is caused by a mutation in the cytosolic enzyme phosphomannose isomerase (MPI). The enzyme catalyzes the conversion of fructose-6-phosphate to mannose-6-phosphate [49], and therefore the disease is characterized by decreased mannose-6-phosphate. Mannose supplementation increased the mannose-6-phosphate levels and improved the clinical features in patients [45]. Despite mannose therapy, patients can develop progressive liver failure at a later stage of the disease. One first patient was successfully treated by liver transplantation, resulting in immediate recovery of most severe clinical symptoms [50]. As expected in view of the hepatic origin of transferrin, intact transferrin glycosylation profiles completely normalized after the transplantation. However, the disease status in other organs cannot be followed adequately by analysis of transferrin alone. This clearly shows the need for additional biomarkers for CDG therapy monitoring, including glycoproteins that are synthesized by other tissues and cell types.

PGM1-CDG is caused by a mutation in the phosphoglucomutase 1 enzyme (PGM1). The enzyme catalyzes the interconversion of glucose-6-phosphate and glucose-1-phosphate [51]. The disease was identified by a highly characteristic transferrin glycosylation profile with high-resolution mass spectrometry, which showed a combination of CDG-I and CDG-II. The spectra showed truncated glycans lacking galactose. Based on the spectra and known metabolic pathways, supplementation of patients with galactose resulted in almost complete normalization of transferrin glycosylation [20] (Fig. 2). The normalization of the truncated glycans upon galactose treatment can be explained based on known metabolic pathways. However, the normalization of the complete glycans (CDG-I) cannot be fully explained. More detailed insight into the dynamics and regulation of sugar metabolism, and its link with protein glycosylation, would help us to better understand the glycosylation machinery, further optimize therapy and develop new therapies for other CDG patients. In addition, monitoring of the glycosylation of additional proteins is required to learn if other tissues apart from liver respond equally well to galactose treatment.

SLC35C1-CDG is caused by a mutation in the GDP-fucose transporter in the Golgi-membrane, resulting in hypofucosylation of N-glycopeptides [52]. Patients typically lack sialyl-Lewis X (sLex) structures on the cell surface of neutrophils, which is required for their rolling on endothelial cells before extravasation [53]. This CDG type is therefore also known as leukocyte adhesion deficiency II (LAD II) and leads to infectious complications. Depending on the nature of the mutation, some patients respond to L-fucose application [46, 54]. However, no proper glycoprotein marker is currently available to monitor therapy response and disease progression.

PIGM-CDG is a defect in GPI-anchor biosynthesis and is caused by a mutation in the glycosylphosphatidylinositol glycan (class M) (PIGM) promoter. PIGM transfers the first mannose to the GPI anchor at the luminal side of the endoplasmic reticulum [55]. Mutation in the promoter causes histone hypoacetylation, resulting in defective GPI anchored proteins on blood cells [47]. A patient was therefore treated with sodium phenylbutyrate, which is a histone deacetylase inhibitor. This increased PIGM transcription, resulting in improved GPI anchored glycoproteins: CD59 (MAC-inhibitory protein) on erythrocytes and CD59 and CD24 (heat stable antigen) on granulocytes (FACS analysis) [55]. Clinically, the patient improved and was able to walk again and had no more seizures [48].

Currently, CDG therapy monitoring is mainly based on clinical features, transferrin analysis or flow cytometry of several glycoprotein surface markers on blood cells. The main advantage of using transferrin as a biomarker for CDG is its high abundance in blood, allowing fast, detailed and sensitive detection of N-glycosylation in small sample volumes. Also for treatment of fructosemia, a common secondary cause of CDG, the loss of intact glycans can be monitored sensitively by high resolution mass spectrometry of transferrin [31]. However, therapy monitoring in clinical diagnostics is very limited with the analysis of transferrin, and additional biomarkers are essential for the development and monitoring of new and current therapies.

**Novel glycoprotein biomarkers for CDG**

**The need for glycoprotein biomarkers beyond transferrin**

Although transferrin is a very useful diagnostic biomarker for most CDG types with deficient N-glycosylation, several defects in the N-glycosylation pathway are known with a normal transferrin profile. These include both CDG-I subtypes (TUSC3-CDG, ALG13-CDG, ALG14-CDG), Golgi glycosylation defects (GCS1-CDG, SLC35A3-CDG and SLC35C1-CDG), as well as defects in sugar metabolism (GNE, PGM3 and GFPT1). The growing list of these type of defects with normal transferrin glycosylation indicates that additional proteins have to be included for correct diagnosis. Since glycans can be expressed in a tissue-specific way [56–58], defects in their synthesis will be missed when analyzing only hepatocyte-derived transferrin. Furthermore, analysis of defects in the synthesis of glycan structures not or hardly present on transferrin (such as fucose in SLC35C1-CDG), will require inclusion of additional proteins. Additionally, recent studies indicate the existence of...
regulatory processes in protein-specific glycosylation that we
don’t yet understand. For example, apart from the normal
glycosylation of transferrin, glycosylation of IgG was abnor-
mal in GCS1-CDG patients [59], although GCS1 is ubiqui-
tously expressed. Cohen syndrome due to mutations in
VPS13B shows normal transferrin glycosylation as well, how-
ever, Duplomb et al. found abnormal N-glycan structures by
mass spectrometry of total serum glycans [60]. They identified
a decrease in sialylation and galactosylation of total serum N-
glycans, which indicates deficient Golgi N-glycosylation of
specific proteins. They propose to analyze the highly glyco-
sylated protein intercellular cell adhesion molecule 1 (ICAM-
1) and lysosome-associated membrane protein 2 (LAMP-2) in
blood cells as a pre-screening test for Cohen syndrome.

In addition to defects in the N-glycosylation pathway, there
are many other genetic glycosylation defects (e.g., in O- and
lipid-glycosylation, and synthesis of glycosaminoglycans and
glycophosphatidylinositol (GPI) anchors) for which specific
markers need to be developed, which would be of similar
value as transferrin for defects in the N-glycosylation path-
way. In conclusion, there is a clear need for additional glyco-
protein biomarkers, in addition to transferrin, for efficient di-
agnostics of the full scope of genetic glycosylation defects.

Potential glycoprotein biomarkers for diagnostic
application in CDG

An extensive number of glycoprotein biomarkers is already de-
scribed in the literature for diagnosis of other types of diseases,
particularly for diabetes mellitus [61], Alzheimer’s disease [62],
rheumatoid arthritis or other inflammatory diseases [63, 64], and
cancer [65]. These proteins could be a potential glyco-marker for
CDG as well, because they are readily measurable in biological
matrices, and they have different type of glycosylation, or are
from other origin compared to transferrin.

The analysis of glycoprotein levels of some cancer bio-
markers is FDA approved as prognostic or diagnostic screening
[66–68], indicated by an asterisk in the table below. The detection
of most glycoproteins is still mainly based on immunoassays and
electrophoresis techniques, although the application of mass
spectrometric screening is starting to be explored as well. To
highlight the extent of today’s glycoproteomic biomarker re-
search, Table 1 provides an overview of some key examples of
candidate glycoprotein biomarkers from recent literature for the
previously mentioned diseases.

As can be seen from this overview, the number of glycopro-
teins as diagnostic biomarker is growing for multiple diseases,
see Table 1 for details and references. For some of these glyco-
proteins, altered glycosylation has already been investigated in
more detail using mass spectrometry. In particular core or sLeX
fucosylation seems to be a frequent significant change observed.
It should also be noted that the glycoprotein level is often the
diagnostic parameter. So ideally, both protein levels and glyco-
sylation analysis should be included in one assay. It could be
envisioned that combination of several plasma proteins with a
more heterogeneous glycan composition and increased
fucosylation as compared to transferrin, can be used in a panel
to further increase the diagnostic efficiency for CDG-I and CDG-

Fig. 2 Effects of Dietary
Galactose on Glycosylation. High
resolution mass spectrometry
showing glycan structures of
transferrin before (a) and after (b)
2 weeks intake of supplementary
galactose and corresponding
patterns of transferrin isoelectric
focusing (IEF). The protein
backbone is symbolized by a
brown horizontal line. The
unoccupied positions are
indicated by open arrows (↓)
and define the CDG-I-component
of this phenotype. The yellow
arrow (↑) demonstrates the
absence of galactose on one of the
truncated glycans, which define
the CDG type-II component. The
number of sialic acids is indicated
above each structure, and the
insets at the right show respective
IEF results.
Table 1 Overview of some key examples of serum glycoprotein biomarkers from recent literature for diseases that present with altered glycoprotein levels and glycosylation abnormalities

| Glycoprotein Biomarker       | Disease                                    | Detection on protein levels or altered glycoforms | Detection technique          | Reference |
|------------------------------|--------------------------------------------|--------------------------------------------------|------------------------------|-----------|
| Transferrin                   | CDG                                        | Glycosylation abnormalities                      | IEF, QTOF [50]              | [50]      |
|                               | Sepsis                                     | Decrease in sialylation                          | ELLA [93]                   |           |
|                               | Acute pancreatitis                          | Increased fucosylation                           | LC-MS/MS [94]               |           |
|                               | Ovarian cancer                              | Increase of concentration                        | ELISA [95]                  |           |
| α1-antitrypsin                | CDG                                        | Altered glycosylation                            | 2DE [36]                    |           |
|                               | Chronic obstructive pulmonary disease (COPD) | Decreased concentration                         | ELISA [96]                  |           |
|                               | Liver cirrhosis and liver cancer            | Core and outer arm fucosylation                  | 2DE, MALDI-TOF [97]         |           |
|                               | Lung cancer                                 | Altered glycosylation                            | Lectin microarray, ELISA    | [98]      |
| Haptoglobin                   | CDG                                        | Altered glycosylation                            | 2DE [36]                    |           |
|                               | Long cancer                                 | sLeX increase                                    | HILIC, WAX-HPLC [99]        |           |
|                               | Acute phase ovarian cancer                   | sLeX increase                                    | 2DE, NP-HPLC [100]          |           |
|                               | Stomach cancer                              | sLeX increase                                    | 2DE, LC-MS/MS [101]         |           |
|                               | Pancreatic cancer                           | Fucosylation                                     | MALDI-TOF [102, 103]        |           |
|                               | Rheumatoid arthritis                        | Reduced mannosylation                            | 2DE, MALDI-TOF [104]        |           |
|                               | Pancreatic cancer                           | Changes in sialylation                           | WAX-HPLC [105]              |           |
|                               | Gastric cancer                              | Increase of concentration                        | ELISA [106]                 |           |
| Fetuin                        | Hepatocellular carcinoma (HCC)              | Fucosylation                                     | LC-MS/MS [107]              |           |
|                               | Chronic pancreatitis, pancreatic cancer      | sLeX increase                                    | 2DE, WAX-HPLC, LC-MS/MS, MALDI-TOF |           |
|                               | Pancreatic cancer                           | Altered mannosylation                            | 2DE, MALDI-TOF [108]        |           |
|                               | Rheumatoid arthritis                        | Altered mannosylation                            | WAX-HPLC [109]              |           |
| α-1-acid glycoprotein         | CDG                                        | Altered glycosylation                            | 2DE [36]                    |           |
|                               | Acute phase ovarian cancer                   | sLeX increase                                    | 2DE, NP-HPLC [100]          |           |
|                               | Chronic pancreatitis, pancreatic cancer      | Increased branching and sLeX                     | 2DE, WAX-HPLC, LC-MS/MS, MALDI-TOF |           |
|                               | Rheumatoid arthritis                        | Altered mannosylation                            | 2DE, MALDI-TOF [104]        |           |
|                               | Stomach cancer                              | Core fucosylation                                | 2DE, LC-MS/MS [101]         |           |
|                               | Advanced ovarian cancer                      | Reduced galactosylation and sialylation levels    | 2DE, NP-HPLC [100]          |           |
| Immunoglobulin G (IgG)        | Acute phase ovarian cancer                   | sLeX increase                                    | 2DE, NP-HPLC [100]          |           |
|                               | Stomach cancer                              | Core fucosylation                                | 2DE, LC-MS/MS [101]         |           |
|                               | Advanced ovarian cancer                      | Reduced galactosylation and sialylation levels    | 2DE, NP-HPLC [100]          |           |
| α1-antichymotrypsin           | Acute phase ovarian cancer                   | sLeX increase                                    | 2DE, NP-HPLC [100]          |           |
|                               | Alzheimer’s disease                         | Concentration                                    | Immunoblot [108]            |           |
| α,2-macroglobulin             | Sjögren’s syndrome                          | Abnormal glycosylation                           | Immunoassay [109]           |           |
| α-fetoprotein                 | Liver diseases                              | Core fucosylation, concentration                 | 2DE, immunoblot [110]       |           |
| des-γ-carboxypro-thrombin     | Liver diseases, liver cancer                 | Core fucosylation                                | Anti-body (liquid phase binding assay) [110] |           |
| Ferritin                      | Still’s disease, hemophagocytic syndrome     | Altered glycosylation                            | Immunoassay [111]           |           |
| Ceruloplasmin                 | CDG                                        | Low levels, glycosylation abnormalities           | 2DE [50]                    |           |
|                               | Hepatocellular carcinoma (HCC)               | Upregulated, core fucosylation                   | 2DE, MALDI-TOF [112, 113]   |           |
Glycoprotein Biomarker | Disease | Detection on protein levels or altered glycoforms | Detection technique | Reference
--- | --- | --- | --- | ---
Thyroglobulin | Pancreatic cancer | sLeX increase | LC-MS/MS | [114]
Thyrotrpin, Thyroid stimulating hormone | CDG | Low levels, glycosylation abnormalities | 2DE | [50]
| Thyroid cancer | Increase of concentration | Immunoassay | [115], [68]
Thyroglobulin | CDG | Low levels, altered glycosylation | IEF, serum levels | [50, 116, 117]
Hemopexin | Hepatocellular carcinoma (HCC) | Increase of glycoprotein concentration | Immunoassay | [118]
Clusterin | Stomach cancer | Smaller N-glycans | 2DE, LC-MS/MS | [101]
| Gastric cancer | Decrease of concentration | ELISA | [105]
| Clear cell renal cell carcinoma | Decreased (core fucosylated) biantannary glycans | SDS-PAGE, LC-MS/MS | [119]
Leucine rich-α2-glycoprotein α-dystroglycan | Stomach cancer | Upregulation, altered glycosylation | WAX-HPLC | [101, 1120]
Kininogen | Walker-Warburg syndrome | Hypoglycosylation | Immunoassay | [1121]
| Colorectal cancer (CRC) | Elevated sialylation and fucosylation | LC-MS/MS | [122]
| Colorectal cancer (CRC) | Increase of concentration | MALDI-TOF | [123]
| | | ELISA | [119]
| | | Immunostaining | 
Kallistatin | Liver cirrhosis | Increase of concentration | ELISA | [124]
Afamin | Metabolic syndrome | Decrease of concentration | ELISA | [125]
| Gastric cancer | Decrease of concentration | MRM | [105]
Prostate Specific Antigen (PSA) | Prostate cancer | Increase of concentration | Immunoassay | [126], [68]
Human chorionic gonadotrophin (hCG) | Ovarian tumors | Increase of concentration | Immunoassay | [125], [68], [66]
Apolipoprotein (A-1) | Testicular tumors | Increase of concentration | ELISA | [66]
Transferrin, prealbumin | Ovarian cancer | Decrease of concentration | ELISA | [95]
β2-microglobulin | Ovarian cancer | Decrease of concentration | ELISA | [95]
Cancer antigen 125 (CA125) or MUC16 | Ovarian cancer | Increase of concentration | ELISA | [95]
Carbohydrate antigen 19–9 (CA19-9) | Pancreatic cancer | sLeX on mucin glycoproteins | ELISA | [64, 68]
Cancer antigen 15-3 (CA15-3) | Breast cancer | Sialylated O-linked oligosaccharide on MUC1 | ELISA | [67, 68]
CA27-29 (MUC1) | Breast cancer | Protein concentration | ELISA | [67, 68]

2DE 2D-electrophoresis; ELLA enzyme-linked lectin assay; FLISA Lectin-Fluorophore-linked Immunosorbtent Assay; HILIC Hydrophilic Interaction Liquid Chromatography; sLeX Sialyl Lewis A structures; sLeY Sialyl Lewis X structures; WAX-HPLC weak anion exchange high performance liquid chromatography

II. Apart from selections based on biological aspects as discussed in section 4.1, an additional challenge is the mass spectrometric compatibility and the different approaches for analysis, which will be discussed in the next paragraph.

**Mass spectrometry in glycoprotein analysis**

A growing number of protein biomarkers are analyzed in the clinics by mass spectrometry. Mass spectrometry is ideally suited for the clinical laboratory, because the technique is sensitive, compatible with biological matrices, suitable for high-throughput analyses and it provides detailed structural information. The technique has proven itself for CDG diagnostics through the routine analysis of serum transferrin, which will pave the way in the search for additional glycoprotein biomarkers. In Fig. 3, an overview is depicted of the different levels of glycosylation analysis by mass spectrometry, better known as Glycomics. Intact glycoprotein analysis provides quantitative glycan structural information of the intact glycoprotein.
Quantification is possible with the assumption that ionization of the molecules dominated by the amino acid backbone. Loss of complete glycans can therefore accurately be detected. Intact protein analysis is limited by size and hydrophobicity of the protein, and limited by the number of glycosylation sites for correct interpretation of the spectra. Glycopeptide analysis provides detailed site-specific information on glycan forms, and enzymatic digestions increase the chance to measure large or hydrophobic proteins of interest. However, the ionization efficiency is influenced by the type of glycan, which hampers any quantitative comparison between different glycoforms. Analysis of free glycans allows sensitive detection of very low abundant glycan structures, however information on the corresponding protein/peptide attachment site is lost. Therefore, each detection technique has its own strengths and weaknesses depending on the intended goal of the analysis. Below, we discuss the use of mass spectrometry in biomarker discovery and for its potential use as a diagnostic test.

**Glycoprotein biomarker discovery**

The most widely used methods for biomarker discovery within the field of glycomics includes free N-glycan profiling of a biological fluid, such as serum, plasma or cerebrospinal fluid. Many groups have published on the discovery of altered glycosylation in a wide variety of diseases, and convincingly showed that glycans have potential as biomarkers, being highly sensitive to pathological changes [69–73]. Thus far, only a very limited number of potential biomarkers based on free glycan profiling is further developed and used in a real clinical diagnostic test, one example being the GlycoCirrhoTest [74] for distinguishing cirrhotic from non-cirrhotic chronic liver disease patients.

Two major limitations of total serum N-glycan analysis create the basis for improvement: First, the information to which proteins glycans were attached, is lost in total serum N-glycan analysis. Secondly, alterations in glycosylation are biased by fluctuations in the dynamic N-glycoproteome, which are dependent on environmental factors such as an immune response [75–78]. Ideally, profiling methods need to be used that take into account the protein to which the altered glycans are attached, such as profiling of intact glycopeptides from complex biological samples. Recent technical developments and improved databases seem to make this challenge feasible. A combination of collision induced dissociation (CID) and electron-transfer dissociation (ETD) fragmentation techniques is preferred to characterize glycopeptides [79, 80]. While CID provides information related to the composition and structure of glycan moieties attached to a peptide backbone, ETD fragments mainly the peptide backbone and leaves the glycan intact, permitting de novo sequencing of the peptide moiety [81, 82]. Due to the relative low abundance and low ionization efficiency of glycopeptides, glycoproteins need to be enriched, digested and chromatographically separated for this type of analyses. Since the glycan moiety makes the glycopeptide generally more polar, HILIC is a commonly used enrichment strategy for glycopeptides [83]. Other usual approaches are immune-affinity (reactive beads) [84, 85] or lectin-affinity purifications [86, 87]. Furthermore, commercial kits are available to deplete serum samples from the most abundant serum proteins, although that might cause potential biomarkers (see Table 1) to be lost. Combining these techniques enables unambiguous in-depth identification of both the peptide and the glycan. However, the data analysis software is not yet sophisticated enough to enable automated sequencing of peptides and combining search results from both fragmentation techniques for identification. Therefore, intact glycopeptide analysis from complex biological samples is still far from being a routine diagnostic analysis. Within a research environment, glycopeptide profiling is highly promising for the identification of new glycoprotein biomarkers.

One first example of glycopeptide analysis using the combination of CID and ETD fragmentation, is a very recent study of Medzihradszky et al. on tissue-specific glycosylation [58, 88]. They compared the glycosylation patterns of mouse liver and brain tissue and not only found that these patterns differ by the cellular location of the glycoprotein (e.g., ER, lysosomal or transmembrane), but also showed tissue-specific differences for the same protein.

**Glycoprotein biomarker application in clinical diagnostics**

Diagnostic assays are required to be fast, robust and suitable for high-throughput measurements, while in addition the interpretation in a clinical setting should be straightforward. Free N-glycan analysis meets the technical requirements, however, diagnostic interpretation is highly complicated due to the many causes that influence N-glycan profiles. For some well-defined CDG subtypes with a clear genetic defect, such as B4GALT1-CDG and MGAT2-CDG, interpretation is clear. However, abnormalities in free N-glycan profiles for other defects are more subtle or overlapping with multiple defects. Examples include PGM1-CDG, where the lack of complete glycans is not found in total serum N-glycan profiles and only minimal loss of galactose is not sufficiently specific to reach a diagnosis.

Diagnostic application of glycopeptides is of particular interest, because multiple identified biomarkers could subsequently be used for diagnostic high-throughput screening by means of multiple/serial reaction monitoring (MRM/SRM), similar as is increasingly used for the detection of protein biomarkers in clinical diagnostics. In this sensitive targeted analysis, specific (transitions of) predefined precursor ions are sequentially selected for MS/MS detection in a quantitative and reproducible manner [89]. For instance, Hong et al. developed an MRM analysis to analyze the IgG free glycans in whole serum. By normalizing protein glycosylation to
absolute protein concentrations they were able to examine quantitative changes in glycosylation at site-specific level [90], which is crucial to distinguish between altered glycosylation and change in protein levels. Hulsmeier et al. published a MRM method to quantify the N-glycosylation site occupancy for transferrin and α1-antitrypsin, and found out that the site occupancy correlated well with the severity of the disease [91]. Moreover, they observed preferences for specific occupation sites. The method could in principle easily be extended to multiple glycoproteins.

Very recently, Sun et al. proposed a new method to measure absolute protein glycosylation stoichiometry in complex biological samples [92]. They use the relative ratios between the N-glycosylated peptide, the peptide without the glycans and the complete glycoprotein from the same type of biological sample to profile the glycosylation occupancy and glycoform stoichiometry and determined 117 absolute N-glycosylation occupancies in OVCAR-3 cells. Application to CDG has not been tested yet, but might be promising in biomarker discovery.

A specific set of intact glycoproteins would have several advantages over glycopeptide mixtures, mainly improving on the relative quantification. One needs to consider that transferrin is a relative simple glycoprotein to analyze as it has only two glycosylation sites, whereas other proteins might go up to multiple glycosylation sites and increased glycan heterogeneity. Each additional glycosylation site will complicate annotation [83]. In addition, an antibody would be required to affinity-purify the protein from the biological complex sample. The antibody would need to have its epitope outside of any glycosylation motif, to ensure glycosylation-independent purification of all glycoforms.

Overall, each method has its strengths and weaknesses. Targeted, MRM based mass spectrometry of glycopeptides is fast, robust and sensitive, allowing complex mixtures to be analyzed. With intact glycoprotein analysis, a limited number of proteins can be analyzed. However, all glycoforms of one protein are measured simultaneously in the mass spectrometer, which allows relative quantification of glycoforms and easy comparison of both CDG type-I and CDG type-II defects in one spectrum.

**Outlook**

The ultimate goal in clinical diagnostics of CDG would be to cover the complete field of glycosylation disorders in a single or only few assays. This would not only benefit diagnostics of monogenic, inherited disorders of glycosylation, but also the more common, complex genetic disorders like cancer, Alzheimer or inflammatory diseases. Several diseases show abnormal glycosylation, and an increasing number of glycosylation disorders is identified by next generation sequencing techniques. More and more defects within the newly discovered disorders are found outside the pathway of protein N-glycosylation, for example defects in energy metabolism, or GPI-defects. To include these defects, the repertoire of glycoprotein biomarkers should be expanded, by analyzing a well-defined set of multiple, intact biomarker glycoproteins.
Table 1 provides an overview of glycoprotein biomarkers, which are worth considering for clinical diagnostics of CDG. It lists candidates which are already applied in clinical laboratories for other types of diseases, so addition of these proteins should be feasible. Our preference is to include several proteins in one assay, either as glycopeptides or as intact proteins. The intact transferrin spectra already show the potential to develop a unique classification system for CDG. The spectra provide such a characteristic profile that clinical diagnostics is possible at a glance [20, 43].

When glycoproteins are digested, housekeeping proteins or non-glycosylated peptides of a targeted glycoprotein are necessary for normalization and quantification purposes. In addition, improved ionization and enhanced separation for low abundant glycopeptides might be required. When followed by high-resolution detection and adequate databases for automated searches, automated MRM analyses can be used as a fast diagnostic test. Until then, we propose that intact glycoprotein profiling of well-defined protein mixtures will have the best potential for CDG diagnostics and therapy monitoring in the near future.

In conclusion, simultaneous analysis of multiple glycoproteins would highly increase our knowledge of the glycosylation machinery in different types of cells, and improve our diagnostic power to sensitively and specifically monitor disease in CDG patients. A highly detailed glycosylation read-out of individual proteins would work in synergy with Next Generation Sequencing techniques in the identification of new inherited disorders. Also, the diagnostics of more common disorders shall benefit from the lessons that will be learned from the analysis of complex glycoprotein mixtures.

Acknowledgments This work was supported by the Dutch Organisation for Scientific Research, NWO (Medium Investment Grant 40-00506-98-9001 and VIDI Grant 91713359 to DL).

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Mechref, Y., et al.: Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis 33(12), 1755–1767 (2012)
2. Miwa, H.E., et al.: The bisecting GlcNAc in cell growth control and tumor progression. Glycoconj. J. 29(8–9), 609–618 (2012)
3. Büll, C., et al.: Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol. Cancer Ther. 12(10), 1935–1946 (2013)
4. Gornik, O., Lauc, G.: Glycosylation of serum proteins in inflammatory diseases. Dis. Markers 25(4–5), 267–278 (2008)
5. Schedin-Weiss, S., Winblad, B., Tjernberg, L.O.: The role of protein glycosylation in Alzheimer disease. FEBS J. 281(1), 46–62 (2014)
6. Bunn, H.F., Gabbay, K.H., Gallop, P.M.: The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200(4337), 21–27 (1978)
7. Thanabalasingham, G., et al.: Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes 62(4), 1329–1337 (2013)
8. Freeze, H.H., et al.: Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am. J. Hum. Genet. 94(2), 161–175 (2014)
9. Jaeken, J.: CDG nomenclature: time for a change! Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1792(9), 825–826 (2009)
10. Jaeken, J., van den Heuvel L.: Congenital disorders of glycosylation, in physician’s guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases. Springer. p. 483–512 (2014)
11. Hennet, T.: Diseases of glycosylation beyond classical congenital disorders of glycosylation. Biochimica et Biophysica Acta (BBA)-General Subjects 1820(9), 1306–1317 (2012)
12. Scott, K., et al.: Congenital disorders of glycosylation: new defects and still counting. J. Inherit. Metab. Dis. 37(4), 609–617 (2014)
13. Grünewald, S., Matthijs, G., Jaeken, J.: Congenital disorders of glycosylation: a review. Pediatr. Res. 52(5), 618–624 (2002)
14. Wolfe, L.A., Krasnewich, D.: Congenital disorders of glycosylation and intellectual disability. Developmental disabilities research reviews 17(3), 211–225 (2013)
15. Wada, Y.: Mass spectrometry for congenital disorders of glycosylation, CDG. J. Chromatogr. B 838(1), 3–8 (2006)
16. Morelle, W., Michalski, J.-C.: Analysis of protein glycosylation by mass spectrometry. Nat. Protoc. 2(7), 1585–1602 (2007)
17. Guillard, M., et al.: Automated measurement of permethylated serum N-glycans by MALDI-linear ion trap mass spectrometry. Carbohydr. Res. 344(12), 1550–1557 (2009)
18. Sturiale, L., Barone, R., Garozzo, D.: The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation. J. Inherit. Metab. Dis. 34(4), 891–899 (2011)
19. Lacey, J.M., et al.: Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin. Chem. 47(3), 513–518 (2001)
20. Tegtmeier, L.C., et al.: Multiple phenotypes in phosphoglucomutase 1 deficiency. N. Engl. J. Med. 370(6), 533–542 (2014)
21. Matthijs, G., et al.: Approaches to homozygosity mapping and exome sequencing for the identification of novel types of CDG. Glycoconj. J. 30(1), 67–76 (2013)
22. Jaeken, J.: Congenital disorders of glycosylation. Ann. N. Y. Acad. Sci. 1214(1), 190–198 (2010)
23. Jaeken, J., et al.: Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome. Clin. Chim. Acta 144(2), 245–247 (1984)
24. Helander, A., Hsa, A., Jeppsson, J.-O.: Improved HPLC method for carbohydrate-deficient transferrin in serum. Clin. Chem. 49(11), 1881–1890 (2003)
25. Carchon, H.A., et al.: Diagnosis of congenital disorders of glycosylation by capillary zone electrophoresis of serum transferrin. Clin. Chem. 50(1), 101–111 (2004)
26. Sanz-Nebot, V., et al.: Characterization of transferrin glycoforms in human serum by CE-UV and CE-ESI-MS. Electrophoresis 28(12), 1949–1957 (2007)
27. Lefebre, D.J., Morava, E., Jaeken, J.: How to find and diagnose a CDG due to defective N-glycosylation. J. Inherit. Metab. Dis. 34(4), 849–852 (2011)
28. Albahri, Z., et al.: Genetic variants of transferrin in the diagnosis of protein hypoglycosylation. J. Inherit. Metab. Dis. 28(6), 1184–1188 (2005)
29. Zühlke-Dorf, A., et al.: Transferrin variants: Pitfalls in the diagnostics of congenital disorders of glycosylation. Clin. Biochem. 48(1), 11–13 (2015)
30. Kühnl, P., Spielmann, W.: Transferrin: evidence for two common subtypes of the TIC allele. Hum. Genet. 43(1), 91–95 (1978)
31. van Scherpenzeel, M., et al.: High-resolution QToF-MS glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital disorders of glycosylation. Translational Res. (2015)
32. Jaeken, J.: Congenital disorders of glycosylation (CDG): it’s (nearly) all in it! J. Inherit. Metab. Dis. 34(4), 853–858 (2011)
33. Gao, N., Lehrman, M.A.: Analyses of dolichol pyrophosphate-linked oligosaccharides in cell cultures and tissues by fluorophore-assisted carbohydrate electrophoresis. Glycobiology 12(5), 353–360 (2002)
34. Timal, S., et al.: Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. Hum. Mol. Genet. 21(19), 4151–4161 (2012)
35. Wopereis, S., et al.: Transferrin and apolipoprotein C-III isofocusing are complementary in the diagnosis of N- and O-glycan biosynthesis defects. Clin. Chem. 53(2), 180–187 (2007)
36. Wada, Y., Tajiri, M., Yoshida, S.: Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics. Anal. Chem. 76(22), 6560–6565 (2004)
37. Guillard, M., et al.: Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. Clin. Chem. 57(4), 593–602 (2011)
38. Xia, B., et al.: Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation. Anal. Biochem. 442(2), 178–185 (2013)
39. Wada, Y., Kadoya, M., Okamoto, N.: Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARC2L) patient. Glyobiology 22(8), 1140–1144 (2012)
40. Xie, T., et al.: A rapid mass spectrometric strategy for the characterization of N- and O-glycan chains in the diagnosis of defects in glycan biosynthesis. Proteomics 7(11), 1800–1813 (2007)
41. Kim, H., et al.: MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. Comparison with two-dimensional electrophoresis. PROTEOMICSClinical Applications, (2015)
42. Van Scherpenzeel, M., et al.: Diagnostic serum glycosylation profile in patients with intellectual disability as a result of MAN1B1 deficiency. Brain 137(4), 1030–1038 (2014)
43. Freeze, H.H.: Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-la patients. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1792(9), 835–840 (2009)
44. De Lonlay, P., Seta, N.: The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-la. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1792(9), 841–843 (2009)
45. Marquardt, T., et al.: Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 94(12), 3976–3985 (1999)
46. Almeida, A.M., et al.: Targeted therapy for inherited GPI deficiency. N. Engl. J. Med. 356(16), 1641–1647 (2007)
47. Freeze, H.H., Aebi, M.: Molecular basis of carbohydrate-deficient glycoprotein syndromes type I with normal phosphomannomutase activity. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1455(2), 167–178 (1999)
48. Quick, C.B., Fisher, R.A., Harris, H.: A kinetic study of the iso-enzymes determined by the three human phosphoglucomutase loci PGM1, PGM2 and PGM3. Eur. J. Biochem. 42(2), 511–517 (1974)
49. Faid, V., et al.: A rapid mass spectrometric strategy for the characterization of N- and O-glycan chains in the diagnosis of defects in glycan biosynthesis. Proteomics 3(4), 593–602 (2003)
50. Almeida, A.M., et al.: Targeted therapy for inherited GPI deficiency. N. Engl. J. Med. 356(16), 1641–1647 (2007)
51. Marquardt, T., et al.: Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J. Pediatr. 134(6), 681–688 (1999)
52. Medzirahrsky, K., et al.: Essentials of glycobiology. 2nd ed. Chapter 13: Glycosylation at the glycopeptide level. Mol. Cell. Proteomics M115, 050393 (2015)
53. Medzirahrsky, K., et al.: Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N. Engl. J. Med. 370(17), 1615–1625 (2014)
54. Duplomb, L., et al.: Cohen syndrome is associated with major glycosylation defects. Human molecular genetics, p. ddtt630 (2013)
55. Testa, R., et al.: N-Glycan profiling of serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One 10(3), e0119983 (2015)
56. Kitazume, S.: Glycosylation of amyloid β precursor protein, pp. 1283–1288. Biology and Medicine, Glycoscience (2015)
57. Albrecht, S., et al.: Glycosylation as a marker for inflammatory arthritis. Cancer Biomark 14, 17–28 (2014)
58. Angata, T., et al.: Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. Amn. N. Y. Acad. Sci. 1253(1), 159–169 (2012)
59. Adamczyk, B., Tharmalingam, T., Rudd, P.M.: Glycans as cancer biomarkers. Biochimica et Biophysica Acta (BBA)-General Subjects 1820(9), 1347–1353 (2012)
60. Ludwig, J.A., Weinstein, J.N.: Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845–856 (2005)
61. Shinozaka, Y., et al.: Native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. Proteomics 9(7), 1939 (2009)
70. Song, T., Aldredge, D., Lebrilla, C.B.: A method for in-depth structural annotation of human serum glycans that yields biological variations. Anal. Chem. 87(15), 7754–7762 (2015)
71. Leymarie, N., Zaia, J.: Effective use of mass spectrometry for glycan and glycopeptide structural analysis. Anal. Chem. 84(7), 3040–3048 (2012)
72. Wuhrer, M.: Glycomics using mass spectrometry. Glycobiol. J. 30(1), 11–22 (2013)
73. Stoeckmann, H., et al.: Ultra-high throughput, ultrafiltration-based N-glycomics platform for ultra-performance liquid chromatography (ULTRA3). Analytical Chem. (2015)
74. Callewaert, N., et al.: Noninvasive diagnosis of liver cirrhosis using DNA sequencing-based total serum protein glycomics. Nat. Med. 10(4), 429–434 (2004)
75. Ota, H., et al.: Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Virechows Arch. 433(5), 419–426 (1998)
76. Tangvoranuntakul, P., et al.: Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. 100(21), 12045–12050 (2003)
77. Knezevic, A., et al.: Variability, heritability and environmental determinants of human plasma N-glycome. J. Proteome Res. 8(2), 694–701 (2008)
78. Butler, M., et al.: Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology 13(9), 601–622 (2003)
79. Alley, W.R., Mechref, Y., Novotny, M.V.: Characterization of glycopeptides by combining collision-induced dissociation and electron-transfer dissociation mass spectrometry data. Rapid Commun. Mass Spectrom. 23(1), 161–170 (2009)
80. Mechref, Y.: Use of CID/ETD mass spectrometry to analyze glycopeptides. Current Protocols Protein Sci: p. 12.11. 1–12.11. 11 (2012)
81. Wuhrer, M., et al.: Glycoproteomics based on tandem mass spectrometry of glycopeptides. J. Chromatogr. B 849(1), 115–128 (2007)
82. Ma, B., Johnson R.: De novo sequencing and homology searching. Mol. Cell. Proteomics. 11(2): p. O111. 014902 (2012)
83. Khatri, K., et al.: Confident assignment of site-specific glycosylation stoichiometry and a possible mechanism for fucosylation. Int. J. Cancer 105(1), 79–88 (2004)
84. Ongay, S., et al.: Glycopeptide enrichment and separation for protein glycosylation analysis. J. Sep. Sci. 35(18), 2341–2372 (2012)
85. Yang, Y., Hancock, W.S.: Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. J. Chromatogr. A 1053(1), 79–88 (2004)
86. Trinidad, J.C., et al.: N- and O-glycosylation in the murine sarcomtome. Mol. Cell. Proteomics 12(12), 3474–3488 (2013)
87. Picotti, P., Aebersold, R.: Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods 9(6), 555–566 (2012)
88. Hong, Q., et al.: Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. Anal. Chem. 85(18), 8585–8593 (2013)
89. Hülsmeier, A.J., Paesold-Burda, P., Hennet, T.: N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol. Cell. Proteomics 6(12), 2132–2138 (2007)
90. Sun, S., Zhang H.: Large-scale measurement of absolute protein glycosylation stoichiometry. Analytical Chem. (2015)
91. Gomik, O., et al.: Change of transferin sialylation differs between mild sepsis and severe sepsis and septic shock. Intern. Med. 50(8), 861–869 (2011)
92. Kontro, H., et al.: Comparison of sialylated N-glycopeptide levels in serum of pancreatic cancer patients, acute pancreatitis patients, and healthy controls. Proteomics 14(15), 1713–1723 (2014)
93. Abraham, J.: OVA1 test for preoperative assessment of ovarian cancer. Commun. Oncol. 7(6), 249–250 (2010)
94. Ongay, S., et al.: Glycopeptide enrichment and separation for protein glycosylation analysis. J. Sep. Sci. 30(10), 2803–2808 (2006)
95. Miyoshi, E., Nakano, M.: Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 8(16), 3257–3262 (2008)
96. Stockley, R.A., Turner, A.M.: α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends Mol. Med. 20(2), 105–115 (2014)
97. Comunale, M.A., et al.: Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. (2010)
98. Ma, B., Johnson R.: De novo sequencing and homology searching. Mol. Cell. Proteomics. 11(2): p. O111. 014902 (2012)
99. Arnold, J.N., et al.: Novel glycan biomarkers for the detection of lung cancer. Glycobiology: p. cwu115 (2014)
100. Humphries, J.M., et al.: Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1844(5), 1051–1058 (2014)
101. Saroah, A., et al.: Altered glycosylation and expression of plasma alpha-1-acid glycoprotein and haptoglobin in rheumatoid arthritis. J. Chromatogr. B 879(20), 1839–1843 (2011)
102. Comunale, M.A., et al.: Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J. Proteome Res. 8(2), 595–602 (2008)
103. Sarrats, A., et al.: Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. PROTEOMICS-Clinical Applications 4(4), 432–448 (2010)
104. Lieberman, J., et al.: Serum α-1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol. Aging 16(5), 747–753 (1995)
105. Mehta, A., Block, T.M.: Fucosylated glycoproteins as markers of liver disease. Dis. Markers 25(4–5), 259–265 (2008)
106. Fardet, L., et al.: Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis & Rheumatism 58(5), 1521–1527 (2008)
107. Yin, H., et al.: Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J. Proteome Res. 13(6), 2887–2896 (2014)
113. Comunale, M.A., et al.: Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J. Proteome Res. 5(2), 308–315 (2006)
114. Balmaña, M., et al.: Identification of potential pancreatic cancer serum markers: increased sialyl-Lewis X on ceruloplasmin. Clin. Chim. Acta 442, 56–62 (2015)
115. Baudin, E., et al.: Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. The Journal of Clinical Endocrinology & Metabolism 88(3), 1107–1111 (2003)
116. Mohamed, M., et al.: Thyroid function in PMM2-CDG: diagnostic approach and proposed management. Mol. Genet. Metab. 105(4), 681–683 (2012)
117. Macchia, P.E., et al.: Thyroid function tests and characterization of thyroxine-binding globulin in the carbohydrate-deficient glycoprotein syndrome type I. The Journal of Clinical Endocrinology & Metabolism 80(12), 3744–3749 (1995)
118. Ross, D.S.: Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol. Metab. Clin. N. Am. 30(2), 245–264 (2001)
119. Gbormittah, F.O., et al.: Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma. J Proteome Res, (2015)
120. Kakisaka, T., et al.: Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J. Chromatogr. B 852(1), 257–267 (2007)
121. van Reeuwijk, J., et al.: POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J. Med. Genet. 42(12), 907–912 (2005)
122. Qiu, Y., et al.: Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J. Proteome Res. 7(4), 1693–1703 (2008)
123. Wang, J., et al.: Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One 8, e70519 (2013)
124. Cheng, Z., et al.: Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharmaceutica Sinica B, (2015)
125. Dieplinger, H., Dieplinger, B.: Afamin—A pleiotropic glycoprotein involved in various disease states. Clin. Chim. Acta 446, 105–110 (2015)
126. Gilgunn, S., et al.: Aberrant PSA glycosylation—a sweet predictor of prostate cancer. Nature Reviews Urology 10(2), 99–107 (2013)